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To the Editor,
We wish to bring your attention to the PsoPROTECT (Psoriasis Patient Registry for Outcomes, Therapy and 
Epidemiology of Covid-19 infecTion) and SECURE-AD (Surveillance Epidemiology of Coronavirus Under 
Research Exclusion-Atopic Dermatitis) registries; two urgent global initiatives that address an unmet need 
for delineating the determinants of COVID-19 outcomes in the common cutaneous immune-mediated 
inflammatory diseases (IMIDs) psoriasis and atopic dermatitis. 
The highly transmissible coronavirus disease 2019 (COVID-19), caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has created an unprecedented global public health emergency. 
The pandemic has placed an immense strain on healthcare systems and societal infrastructure worldwide. 
Most patients exhibit mild-to-moderate symptoms and recover without sequelae, however around 15% 
develop severe pneumonia and 5% progress to acute respiratory distress syndrome, septic shock and/or 
multiple organ failure, associated with high mortality1. There is an urgent need to better delineate the risk 
factors leading to poorer outcomes, with emerging data suggesting the elderly and those with pre-existing 
comorbid conditions such as cardiovascular disease, poorly controlled asthma and diabetes are at highest 
risk2. 
Although the precise mechanisms by which SARS-CoV-2 causes severe illness are not known, exaggerated 
innate inflammatory and impaired adaptive immune responses have been observed1. Given the 
immunopathogenesis and treatment paradigm of IMIDs, this group of conditions poses a particular 
management challenge in the pandemic, and also a potential opportunity to gain insight into the host 
immune response to the virus. 
Both psoriasis and atopic dermatitis are associated with multimorbidity and typified by innate and 
adaptive immune dysregulation, which is targeted by immunomodulatory therapies3,4. In the context of 
COVID-19, the broad immune-suppression conferred by conventional systemic agents, such as 
methotrexate, may downregulate protective host antiviral immune responses. On the other hand, should 
treatment need to be paused in the pandemic, the longer half-life and particular pharmacokinetics of 
biological therapies will limit the speed of their systemic clearance. Although real-world observational 
data suggest an increased risk of serious infections with some agents5,6, their relative safety in relation to 
COVID-19 is unknown7. Conversely, there is a theoretical protective role of immunomodulators in 
attenuating a severe systemic inflammatory response to infection. JAK inhibitors (which have 
demonstrated efficacy in psoriasis and atopic dermatitis in clinical trials) and interleukin-1 inhibitors are 
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potential pathogenic role for upregulated innate antiviral immune responses in psoriasis3, however, it is 
unclear whether this has implications for risk or outcome of COVID-19.   
To address these gaps, the international clinical, scientific and public health dermatological communities 
have rapidly connected with the common aim of gathering observational data on COVID-19 outcomes in 
psoriasis and atopic dermatitis on a global scale. PsoPROTECT (www.psoprotect.org) and SECURE-AD 
(www.covidderm.org) are web-based registries for clinicians to report COVID-19 outcomes in psoriasis 
and atopic dermatitis, respectively. They have received robust support from major international 
dermatological professional and patient organisations, and wide participation of clinicians is now vital.  
Global case reporting in PsoPROTECT and SECURE-AD
Clinicians worldwide are invited to complete the short web-based PsoPROTECT and SECURE-AD case 
report forms for any cases of confirmed or suspected COVID-19 in psoriasis and atopic dermatitis. The 
forms collect patient demographics, comorbidities, change in psoriasis/atopic dermatitis severity during 
COVID-19, immunomodulator medications (including drug exposure prior to/during the illness), and 
COVID-19 symptoms, management and outcome. The rapid adoption of virtual care models in the current 
pandemic has transformed the landscape of dermatological practice and is highly conducive to reporting 
cases of COVID-19 via PsoPROTECT and SECURE-AD. Data are collected online and processed solely for the 
purpose of medical research undertaken in the public interest. No patient identifiers are collected, and 
the data are housed on secure servers. 
Scope of new knowledge and data sharing
The accumulating prospective observational clinical datasets in PsoPROTECT and SECURE-AD, alongside 
emerging data in the scientific literature, may help to guide clinical decision making during the pandemic. 
A key objective is to identify predictors (e.g. immunomodulator medications, comorbidities, demographic 
variables) of COVID-19 outcomes in psoriasis and atopic dermatitis and to characterise patients in whom it 
may be beneficial to pause, continue or initiate systemic treatment. Regular open-access summaries of 
aggregated data will be published online for the benefit of the global clinical and patient community. 
Researchers are also actively encouraged to apply to utilise the registry data.
Importantly, these data have the potential to generate hypotheses on the underlying immunological basis 
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scientific basis and mode of action of immunomodulators in psoriasis and atopic dermatitis has been 
rigorously evaluated3,4, so any emerging novel associations of these therapies or disease-specific 
characteristics with COVID-19 outcomes may provide insight into pathomechanisms of the infection 
beyond these conditions and dermatology. 
Cross-disease collaboration
Subsets of patients will be compared to determine the impacts on COVID-19 outcomes of specific 
immunomodulators/drug classes, disease severity and demographic variables such as age, sex, ethnicity 
and geographical regions. Cross-IMID comparisons are also important, since individual diseases may 
confer differential risks on COVID-19 outcome. The data fields in PsoPROTECT and SECURE-AD case report 
forms are therefore aligned with those of similar global efforts in rheumatology (https://rheum-covid.org/) 
and inflammatory bowel disease (https://covidibd.org/). Since treatments such as TNF-antagonists are 
shared across IMIDs, greater power to infer impact of specific immunomodulators on outcomes may be 
afforded by combining disease datasets. 
Limitations and mitigation strategies
Any preliminary data should be interpreted with caution, particularly where case numbers are limited. An 
observational design is necessary for the capture of real-world outcomes in the registries, however there 
is inevitable potential for bias and incomplete data capture. For instance, clinicians may be more likely to 
report, and in more severe/complex skin disease, in better-resourced health care systems. In the context 
of a global case collection, cross-national differences in public health strategies will also need to be 
accounted for when interpreting outcome data.
A limitation of registries relying on spontaneous reporting is a lack of denominator data for each 
treatment. To help to mitigate this, data from PsoPROTECT and SECURE-AD can be used to enrich existing 
large-scale pharmacovigilance registries. Subsequent meta-analyses may give more precise estimates of 
the risks associated with each drug/variable. 
Patient-reported outcomes of COVID-19, patient experiences and health behaviours during the pandemic 
are also key considerations for informing clinical care. Therefore, patient-led collections of data will be 
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and SECURE-AD. This will enable inclusion of individuals with milder psoriasis and atopic dermatitis, and 
also less severe COVID-19 infections, reducing the risk of selection bias. 
Conclusion
Close international collaboration between clinicians, scientists and patients in the current pandemic is 
essential to fulfil PsoPROTECT and SECURE-AD’s exciting potential to rapidly accrue large-scale datasets 
with high translational value. The knowledge gained from these efforts will be vital for guiding treatment 
choices and counselling patients on how to mitigate the potential risk of COVID-19.  
Please help to inform our common clinical practice in the coming weeks and months by reporting your 
cases of COVID-19 today.
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